AbbVie reports 2024 financial results: Revenue growth driven by immunology and neuroscience

AbbVie (NYSE: ABBV) has released its full-year and fourth-quarter 2024 financial results, showing continued revenue growth despite challenges such as the U.S. loss of exclusivity ... Read More